A bridging stent to surgery in patients with esophageal and gastroesophageal junction cancer has a dramatic negative impact on patient survival: A retrospective cohort study through data acquired from a prospectively maintained national database

D W Kjaer; M Nassar; L S Jensen; L B Svendsen; F V Mortensen

doi:10.1111/dote.12474

A bridging stent to surgery in patients with esophageal and gastroesophageal junction cancer has a dramatic negative impact on patient survival: A retrospective cohort study through data acquired from a prospectively maintained national database

D W Kjaer, M Nassar, L S Jensen, L B Svendsen, F V Mortensen

Institut for Klinisk Medicin

7 Citationer (Scopus)

Abstract

This study aimed to assess the impact of esophageal stenting on postoperative complications and survival in patients with obstructing esophageal and gastroesophageal junction (GEJ) cancer. All patients treated without neoadjuvant therapy that had an R0-resection performed for esophageal and GEJ cancer between January 2003 and December 2010 were identified from a prospectively maintained database. Data on stenting, postoperative mortality, morbidity, recurrence-free survival, complications, and length of hospital stay were collected. Kaplan-Meier plots for survival and recurrence-free survival curves were constructed for R0 resected patients. Data were compared between the stent and no-stent group by nonparametric tests. Two hundred seventy three consecutive R0 resected patients with esophageal or GEJ cancer were identified. Of these patients, 63 had a stent as a bridge to surgery. The male/female ratio was 2.64 (198/75) with a median age in the stent group (SG) of 65.1 versus 64.3 in the no stent group (NSG). Patients were comparable with respect to gender, age, smoking, TNM-classification, oncological treatment, hospital stay, tumor location, and histology. The median survival in the SG was 11.6 months compared with 21.3 months for patients treated without a bridging stent (P < 0.001). There were no statistically significant differences in 30-day mortality between the two groups, but NSG patients exhibited a significantly better two-year survival (P = 0.017). The median recurrence-free survival was 9.1 months for the SG compared with 15.2 months for the NSG. The use of a stent as a bridging procedure to surgery in patients treated without neaoadjuvant therapy for an esophageal or GEJ cancer that later underwent R0 resection decreased the two year survival and the recurrence-free survival.

Originalsprog	Engelsk
Tidsskrift	Diseases of the Esophagus
Vol/bind	30
Udgave nummer	3
Sider (fra-til)	1-7
Antal sider	7
ISSN	1120-8694
DOI	https://doi.org/10.1111/dote.12474
Status	Udgivet - 1 mar. 2017

FN’s Verdensmål

Dette resultat bidrager til følgende verdensmål

Adgang til dokumentet

10.1111/dote.12474

Fingeraftryk

Dyk ned i forskningsemnerne om 'A bridging stent to surgery in patients with esophageal and gastroesophageal junction cancer has a dramatic negative impact on patient survival: A retrospective cohort study through data acquired from a prospectively maintained national database'. Sammen danner de et unikt fingeraftryk.

Citationsformater

Kjaer, D. W., Nassar, M., Jensen, L. S., Svendsen, L. B., & Mortensen, F. V. (2017). A bridging stent to surgery in patients with esophageal and gastroesophageal junction cancer has a dramatic negative impact on patient survival: A retrospective cohort study through data acquired from a prospectively maintained national database. Diseases of the Esophagus, 30(3), 1-7. https://doi.org/10.1111/dote.12474

A bridging stent to surgery in patients with esophageal and gastroesophageal junction cancer has a dramatic negative impact on patient survival: A retrospective cohort study through data acquired from a prospectively maintained national database. / Kjaer, D W; Nassar, M; Jensen, L S et al.
I: Diseases of the Esophagus, Bind 30, Nr. 3, 01.03.2017, s. 1-7.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Kjaer, DW, Nassar, M, Jensen, LS, Svendsen, LB & Mortensen, FV 2017, 'A bridging stent to surgery in patients with esophageal and gastroesophageal junction cancer has a dramatic negative impact on patient survival: A retrospective cohort study through data acquired from a prospectively maintained national database', Diseases of the Esophagus, bind 30, nr. 3, s. 1-7. https://doi.org/10.1111/dote.12474

Kjaer DW, Nassar M, Jensen LS, Svendsen LB, Mortensen FV. A bridging stent to surgery in patients with esophageal and gastroesophageal junction cancer has a dramatic negative impact on patient survival: A retrospective cohort study through data acquired from a prospectively maintained national database. Diseases of the Esophagus. 2017 mar. 1;30(3):1-7. doi: 10.1111/dote.12474

@article{2200554bbb64425297da1568864df805,

title = "A bridging stent to surgery in patients with esophageal and gastroesophageal junction cancer has a dramatic negative impact on patient survival: A retrospective cohort study through data acquired from a prospectively maintained national database",

abstract = "This study aimed to assess the impact of esophageal stenting on postoperative complications and survival in patients with obstructing esophageal and gastroesophageal junction (GEJ) cancer. All patients treated without neoadjuvant therapy that had an R0-resection performed for esophageal and GEJ cancer between January 2003 and December 2010 were identified from a prospectively maintained database. Data on stenting, postoperative mortality, morbidity, recurrence-free survival, complications, and length of hospital stay were collected. Kaplan-Meier plots for survival and recurrence-free survival curves were constructed for R0 resected patients. Data were compared between the stent and no-stent group by nonparametric tests. Two hundred seventy three consecutive R0 resected patients with esophageal or GEJ cancer were identified. Of these patients, 63 had a stent as a bridge to surgery. The male/female ratio was 2.64 (198/75) with a median age in the stent group (SG) of 65.1 versus 64.3 in the no stent group (NSG). Patients were comparable with respect to gender, age, smoking, TNM-classification, oncological treatment, hospital stay, tumor location, and histology. The median survival in the SG was 11.6 months compared with 21.3 months for patients treated without a bridging stent (P < 0.001). There were no statistically significant differences in 30-day mortality between the two groups, but NSG patients exhibited a significantly better two-year survival (P = 0.017). The median recurrence-free survival was 9.1 months for the SG compared with 15.2 months for the NSG. The use of a stent as a bridging procedure to surgery in patients treated without neaoadjuvant therapy for an esophageal or GEJ cancer that later underwent R0 resection decreased the two year survival and the recurrence-free survival.",

keywords = "Aged, Combined Modality Therapy, Databases, Factual, Disease-Free Survival, Esophageal Neoplasms, Esophagectomy, Esophagogastric Junction, Esophagoscopy, Female, Humans, Kaplan-Meier Estimate, Length of Stay, Male, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Prospective Studies, Retrospective Studies, Statistics, Nonparametric, Stents, Treatment Outcome, Evaluation Studies, Journal Article",

author = "Kjaer, {D W} and M Nassar and Jensen, {L S} and Svendsen, {L B} and Mortensen, {F V}",

note = "{\textcopyright} 2016 International Society for Diseases of the Esophagus.",

year = "2017",

month = mar,

day = "1",

doi = "10.1111/dote.12474",

language = "English",

volume = "30",

pages = "1--7",

journal = "Diseases of the Esophagus",

issn = "1120-8694",

publisher = "JohnWiley & Sons, Inc.",

number = "3",

}

TY - JOUR

T1 - A bridging stent to surgery in patients with esophageal and gastroesophageal junction cancer has a dramatic negative impact on patient survival

T2 - A retrospective cohort study through data acquired from a prospectively maintained national database

AU - Kjaer, D W

AU - Nassar, M

AU - Jensen, L S

AU - Svendsen, L B

AU - Mortensen, F V

PY - 2017/3/1

Y1 - 2017/3/1

N2 - This study aimed to assess the impact of esophageal stenting on postoperative complications and survival in patients with obstructing esophageal and gastroesophageal junction (GEJ) cancer. All patients treated without neoadjuvant therapy that had an R0-resection performed for esophageal and GEJ cancer between January 2003 and December 2010 were identified from a prospectively maintained database. Data on stenting, postoperative mortality, morbidity, recurrence-free survival, complications, and length of hospital stay were collected. Kaplan-Meier plots for survival and recurrence-free survival curves were constructed for R0 resected patients. Data were compared between the stent and no-stent group by nonparametric tests. Two hundred seventy three consecutive R0 resected patients with esophageal or GEJ cancer were identified. Of these patients, 63 had a stent as a bridge to surgery. The male/female ratio was 2.64 (198/75) with a median age in the stent group (SG) of 65.1 versus 64.3 in the no stent group (NSG). Patients were comparable with respect to gender, age, smoking, TNM-classification, oncological treatment, hospital stay, tumor location, and histology. The median survival in the SG was 11.6 months compared with 21.3 months for patients treated without a bridging stent (P < 0.001). There were no statistically significant differences in 30-day mortality between the two groups, but NSG patients exhibited a significantly better two-year survival (P = 0.017). The median recurrence-free survival was 9.1 months for the SG compared with 15.2 months for the NSG. The use of a stent as a bridging procedure to surgery in patients treated without neaoadjuvant therapy for an esophageal or GEJ cancer that later underwent R0 resection decreased the two year survival and the recurrence-free survival.

AB - This study aimed to assess the impact of esophageal stenting on postoperative complications and survival in patients with obstructing esophageal and gastroesophageal junction (GEJ) cancer. All patients treated without neoadjuvant therapy that had an R0-resection performed for esophageal and GEJ cancer between January 2003 and December 2010 were identified from a prospectively maintained database. Data on stenting, postoperative mortality, morbidity, recurrence-free survival, complications, and length of hospital stay were collected. Kaplan-Meier plots for survival and recurrence-free survival curves were constructed for R0 resected patients. Data were compared between the stent and no-stent group by nonparametric tests. Two hundred seventy three consecutive R0 resected patients with esophageal or GEJ cancer were identified. Of these patients, 63 had a stent as a bridge to surgery. The male/female ratio was 2.64 (198/75) with a median age in the stent group (SG) of 65.1 versus 64.3 in the no stent group (NSG). Patients were comparable with respect to gender, age, smoking, TNM-classification, oncological treatment, hospital stay, tumor location, and histology. The median survival in the SG was 11.6 months compared with 21.3 months for patients treated without a bridging stent (P < 0.001). There were no statistically significant differences in 30-day mortality between the two groups, but NSG patients exhibited a significantly better two-year survival (P = 0.017). The median recurrence-free survival was 9.1 months for the SG compared with 15.2 months for the NSG. The use of a stent as a bridging procedure to surgery in patients treated without neaoadjuvant therapy for an esophageal or GEJ cancer that later underwent R0 resection decreased the two year survival and the recurrence-free survival.

KW - Aged

KW - Combined Modality Therapy

KW - Databases, Factual

KW - Disease-Free Survival

KW - Esophageal Neoplasms

KW - Esophagectomy

KW - Esophagogastric Junction

KW - Esophagoscopy

KW - Female

KW - Humans

KW - Kaplan-Meier Estimate

KW - Length of Stay

KW - Male

KW - Middle Aged

KW - Neoplasm Recurrence, Local

KW - Neoplasm Staging

KW - Prospective Studies

KW - Retrospective Studies

KW - Statistics, Nonparametric

KW - Stents

KW - Treatment Outcome

KW - Evaluation Studies

KW - Journal Article

U2 - 10.1111/dote.12474

DO - 10.1111/dote.12474

M3 - Journal article

C2 - 27001181

SN - 1120-8694

VL - 30

SP - 1

EP - 7

JO - Diseases of the Esophagus

JF - Diseases of the Esophagus

IS - 3

ER -